



(51) International Patent Classification:

A61K 31/573 (2006.01) *A61P 35/02* (2006.01)
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:

PCT/US2020/032754

(22) International Filing Date:

13 May 2020 (13.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/847,825 14 May 2019 (14.05.2019) US
62/860,739 12 June 2019 (12.06.2019) US
62/899,088 11 September 2019 (11.09.2019) US
20305223.8 03 March 2020 (03.03.2020) EP

(71) Applicant: **SANOI** [FR/FR]; 54, rue La Boétie, 75008 Paris (FR).

(72) Inventor; and

(71) Applicant (for US only): **CAMPANA ZAMBRANO, Frank** [FR/US]; 20 Village Road, Sudbury, Massachusetts 01776 (US).

(72) Inventors: **AUDAT, Heloise**; c/o Sanofi, 54, rue La Boétie, 75008 Paris (FR). **MARION, Sylvia**; c/o Sanofi, 55 Corpo-

rate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US).

(74) Agent: **ONUFYK, Christina** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS OF ADMINISTERING ANTI-CD38 ANTIBODY TO TREAT MULTIPLE MYELOMA




FIG. 1




FIG. 10

(57) Abstract: Provided are methods of treating a human individual having multiple myeloma that comprise administering to the individual 10 mg/kg isatuximab via intravenous infusion, wherein the volume of each infusion of 10 mg/kg isatuximab is 250 ml. Also provided are methods of treating a human individual having multiple myeloma that comprise administering an anti-CD38 antibody in 28-day cycles, wherein the anti-CD38 antibody is administered on Days 1, 8, 15, and 22 of a first 28-day cycle, wherein the CD38-antibody is administered on Days 1 and 15 of every 28-day cycle following the first 28-day cycle; and wherein the anti-CD38 antibody is administered at a dose of 10 mg/kg or 20 mg/kg.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*